rs7927894 — EMSY

Regulatory variant near the EMSY/C11orf30 locus; T allele is the broadest known allergic disease risk allele — associated with atopic dermatitis, asthma, hay fever, and the atopic march

See your personal result for EMSY

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

EMSY — The Epigenetic Gatekeeper of the Skin Barrier

On chromosome 11q13.5, a single regulatory variant, rs7927894, sits near one of the most consequential genes in allergic disease genetics. This locus is the broadest-acting allergic disease susceptibility signal in the human genome, influencing risk for eczema, asthma, hay fever, and the progressive atopic march from early childhood eczema to later-onset respiratory and food allergies.

The Mechanism

EMSY is a chromatin regulatory protein that acts as a transcriptional repressor. It binds chromatin-modifying complexes and silences nearby target genes by altering histone modifications at their promoters. In skin, EMSY's key targets include genes encoding filaggrin11 filaggrin
Filaggrin (FLG) is a structural protein that aggregates keratin filaments in the outermost skin layer and is broken down into natural moisturising factors; loss-of-function FLG mutations are the strongest known single-gene risk factor for eczema, filaggrin-2, and enzymes that synthesise long-chain ceramides — the lipid molecules that seal the space between skin cells and prevent water loss and allergen entry.

Mechanistic studies22 Mechanistic studies
Elias MS, Brown SJ, J Allergy Clin Immunol 2019 — siRNA knockdown and overexpression experiments in organotypic skin models directly demonstrated that reducing EMSY activity enhances barrier development: filaggrin, filaggrin-2, and long-chain ceramide levels all increase when EMSY is silenced. Conversely, overexpression of EMSY reduces these same barrier markers. In skin biopsy samples from atopic dermatitis patients, EMSY nuclear staining is increased compared with non-atopic controls. A second nearby gene, LRRC32 (encoding GARP), lies within the same topologically associating domain and has independently been linked to atopic dermatitis through its role in regulatory T-cell activation and TGF-β signalling, suggesting this locus has at least two distinct mechanisms converging on allergic susceptibility.

The Evidence

rs7927894 was identified in a 2009 genome-wide scan33 2009 genome-wide scan
Esparza-Gordillo et al., Nat Genet — 939 cases and 975 controls in discovery, 2,637 cases and 3,957 controls in replication across European cohorts as the primary GWAS hit for atopic dermatitis at 11q13.5 (combined p=7.6×10⁻¹⁰). Homozygous T allele carriers (TT) had an odds ratio of 1.47 for atopic dermatitis compared with CC individuals; heterozygous CT carriers had intermediate risk consistent with additive inheritance.

The locus has been replicated across multiple independent cohorts. A large meta-GWAS44 large meta-GWAS
Paternoster et al., Nat Genet 2011 — discovery cohort 5,606 affected individuals and 20,565 controls, replication 5,419 and 19,833 confirmed the 11q13.5 locus signal. In the 9,300-participant ALSPAC birth cohort55 9,300-participant ALSPAC birth cohort
Marenholz et al., Hum Mol Genet 2011 — prospective UK birth cohort with longitudinal phenotyping of atopic conditions, the T allele was associated not only with eczema but also with atopic asthma and hay fever, with the strongest effects seen in combined phenotypes: eczema plus asthma (OR=1.50) and eczema plus hay fever (OR=1.37). The population attributable risk fraction was estimated at 9.3% for eczema and approximately 25% for eczema-associated asthma or hay fever — a substantial contribution from a single common variant.

A 2015 meta-analysis66 2015 meta-analysis
Marenholz et al., Nat Commun — 12 populations, 2,428 combined eczema+asthma cases and 17,034 controls confirmed C11orf30/LRRC32 as one of seven loci contributing to the atopic march. The Polish ECAP cohort study77 Polish ECAP cohort study
Ponińska et al., PLoS One 2017 found that the T allele was associated with atopic dermatitis (OR=1.39) and persistent allergic rhinitis (OR=1.24) in a haplotype-dependent manner, with the effect restricted to haplotypes also encoding G at rs7125552.

The interaction with filaggrin mutations88 filaggrin mutations
O'Regan et al., J Allergy Clin Immunol 2010 — 511 Irish pediatric eczema cases and 1,000 controls; FLG mutations carried OR=5.81 is particularly clinically important. The rs7927894 T allele effect is independent of FLG mutations. In a paediatric Polish cohort99 paediatric Polish cohort
Dębińska et al., Postepy Dermatol Alergol 2020 — 188 children under 2 years, carrying both the T allele and a filaggrin loss-of-function mutation raised atopic dermatitis odds to OR=16.41 — far exceeding the effect of either variant alone.

Practical Actions

Early allergen introduction during weaning (4–6 months) significantly reduces food allergy risk in infants with eczema (peanut: LEAP trial, PMID 25705822 — 86% relative risk reduction in high-risk infants). Since rs7927894 T allele carriers are at elevated risk for the full atopic march — including food allergy — early diversified allergen introduction is a priority management strategy.

Interactions

The most clinically important interaction is with filaggrin (FLG) loss-of-function variants (rs61816766, rs12123821 and others). Both loci converge on the same biological pathway — epithelial barrier maintenance — but through different mechanisms: FLG directly encodes the barrier structural protein, while EMSY regulates its transcription. When both vulnerabilities co-occur, barrier dysfunction is substantially amplified (OR exceeding 16 in paediatric cohorts).

The IL13 variant rs20541 (Arg130Gln) operates on the same allergic phenotype from the immune activation side, and the STAT3 variant rs17881320 influences downstream Th2 signalling. The 11q13.5 locus also physically co-localises with LRRC32/GARP, which independently affects regulatory T-cell function through TGF-β — a second mechanism at the same genomic address that compounds this locus's influence on allergic sensitisation.

Genotype Interpretations

What each possible genotype means for this variant.

CC Low EMSY Expression Normal

Common genotype with typical EMSY activity and baseline atopic disease risk

You carry two copies of the C allele at rs7927894, the reference genotype at this position on chromosome 11q13.5. Approximately 40% of people of European descent share this genotype. Your lifetime risk for atopic dermatitis from this variant is at population baseline — roughly 5–10% in Europeans across all triggers and genetic backgrounds.

CT Intermediate EMSY Activity Intermediate

One T allele moderately elevates atopic dermatitis risk and allergic disease susceptibility

The rs7927894 T allele effect is independent of FLG (filaggrin) loss-of-function mutations, so if you also carry FLG risk variants, the effects compound. The locus tags a 9.3% population attributable risk for eczema and approximately 25% for eczema-associated allergic asthma or hay fever in European populations (Marenholz et al., PMID 21429916).

TT High EMSY Activity High Risk

Two T alleles substantially increase eczema, asthma, and hay fever risk

The 11q13.5 locus is the broadest known single GWAS signal for shared allergic disease, and the TT genotype represents the highest-exposure end of that signal.